Sun Pharma board approves plan to raise up to ₹10,000 crore via NCDs
SEBI moved higher in a governance development with October 12 in focus.
· BS Companies
Sun Pharmaceutical Industries has said its board of directors has approved a proposal to raise funds of up to Rs 10,000 crore through the issuance of non-convertible debentures (NCDs). The decision was taken at a meeting of the company's Board of Directors held on October 12, Sun Pharma said in a regulatory filing late on Monday evening.
Key facts
- Dates in focus
- October 12
The analysis
SEBI reported ₹10,000 crore. Those are the figures as filed — what moves the price is how they sit against what the market already expected, not their absolute size.
Against that, the stock is +0.9% on the day at ₹1,777.70, and has returned -11.2% over three months. It sits 11% below its 52-week high. The pharma & healthcare sector has moved -0.9% over the same period, so Sun Pharmaceutical is running 10.3 points behind its peers.
This is a Governance / audit event. Governance events compress the valuation multiple faster than they impair earnings, and the recovery requires a visible remedy rather than time. On the day the stock is +0.9%, so a modest reaction.
Why it matters
- Governance events hit the valuation multiple, not just the earnings — and the de-rating is usually faster than the recovery.
Market context
- In focus: Sun Pharmaceutical (SUNPHARMA), in Pharma & Healthcare.
- Over three months: Sun Pharmaceutical -11.2% against Pharma & Healthcare -0.9% (10.3 points behind).
- Trading well above normal today: Sun Pharmaceutical at 3.4 times its 20-day average volume.
| Company | Price | Day | 1M | 3M | From 52-wk high | Volume vs 20-day | Market cap |
|---|---|---|---|---|---|---|---|
| Sun PharmaceuticalSUNPHARMA · Pharma & Healthcare | ₹1,777.70 | +0.9% | -2.1% | -11.2% | -11.2% | 3.4× | — |
Pharma & Healthcare
1M -0.6% · 3M -0.9%
Sun Pharmaceutical
Prices as of 30 Oct 2026, 16:11 IST. Sector moves are the average of the stocks we track in each sector.
In this story
Related coverage
Regulator orders Sun Pharma to shut Assam plant over eye-drop quality lapses; what you should know
Q2 Results Live: Varun Beverages Q3 Net Profit Rises 14% YoY; Reliance Slips, Sun Pharma Gains Ahead Of Earnings
Sun Pharma Q2 profit falls 36% as litigation costs hit earnings
Stocks To Watch Today: Dixon Tech, Syrma SGS, Sun Pharma, Wipro, Trent Among Others
Pharma company Gufic buys Lodha Avalon duplex in Juhu for ₹236 crore